'Skyrocketing' Drug Prices, Access And Availability In Line For EU Scrutiny
This article was originally published in SRA
The European Commission is to conduct an analysis of the impact of incentives such as data exclusivity, market exclusivity and patent term extensions on innovation, drug pricing, and access to medicines, including generics. The move was requested by member state health ministers who say they are concerned about cases of 'very high and unsustainable price levels' hindering patient access to effective and affordable medicines.
You may also be interested in...
Tying supplementary protection certificates to the price of a product and replacing data exclusivity with data compensation are just two suggestions from a new paper on how EU incentives for pharmaceutical innovation should be overhauled.
A group of more than 30 NGOs has urged the European Commission to consider abolishing the system of granting supplementary protection certificates to pharmaceutical companies, saying it delays generic competition and affects the availability of affordable medicines. A UK-based patent attorney, however, says the assertions made by the NGOs are not supported by the evidence.
Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, has been recommended for conditional marketing authorization in the EU pending the results of an ongoing Phase III study. The conditional approval system itself is under scrutiny regarding the fulfilment of obligations.